Literature DB >> 27003517

Intravitreal Ranibizumab and Aqueous Humor Factors/Cytokines in Major and Macular Branch Retinal Vein Occlusion.

Hidetaka Noma1, Tatsuya Mimura, Kanako Yasuda, Hayate Nakagawa, Ryosuke Motohashi, Osamu Kotake, Masahiko Shimura.   

Abstract

Aqueous humor levels of cytokines and growth/inflammatory factors were measured in 38 patients with macular edema who had major branch retinal vein occlusion (BRVO) or macular BRVO and were treated with intravitreal ranibizumab injection (IRI). Patients with recurrence of macular edema received further IRI as needed. Aqueous humor levels of vascular endothelial growth factor (VEGF), soluble VEGF receptor-1 (sVEGFR-1), and other cytokines/factors were measured. Compared with major BRVO, macular BRVO was associated with lower aqueous humor levels of sVEGFR-1, its ligands (VEGF and placental growth factor), and other growth/inflammatory factors (platelet-derived growth factor-AA, monocyte chemotactic protein-1, soluble intercellular adhesion molecule-1, interleukin-6, and interleukin-8). The mean number of IRI over 6 months was significantly lower in the macular BRVO group than in the major BRVO group. These findings suggest that macular BRVO requires fewer IRI than major BRVO and is associated with lower aqueous humor levels of various growth/inflammatory factors and cytokines.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27003517     DOI: 10.1159/000444923

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  7 in total

1.  Aqueous humor inflammatory cytokine levels and choroidal thickness in patients with macular edema associated with branch retinal vein occlusion.

Authors:  Yerim An; Sung Pyo Park; Yong-Kyu Kim
Journal:  Int Ophthalmol       Date:  2021-03-19       Impact factor: 2.031

2.  Clinical Comparative Study of Intravitreal Injection of Triamcinolone Acetonide and Aflibercept in the Treatment of Diabetic Retinopathy Cystoid Macular Edema.

Authors:  Yanxia Zhu; Jun Li; Songping Yu; Bangxun Mao; Jia Ying
Journal:  Emerg Med Int       Date:  2022-05-18       Impact factor: 1.621

3.  Efficacy of intravitreal Lucentis injection on major and macular branch retinal vein occlusion.

Authors:  Jing Wang; Ying Li; Shu-Fen Fang; Hong Wang
Journal:  BMC Ophthalmol       Date:  2020-07-09       Impact factor: 2.209

Review 4.  Cytokines and the Pathogenesis of Macular Edema in Branch Retinal Vein Occlusion.

Authors:  Hidetaka Noma; Kanako Yasuda; Masahiko Shimura
Journal:  J Ophthalmol       Date:  2019-05-02       Impact factor: 1.909

5.  Efficacy of Modified Treat-and-Extend Aflibercept Regimen for Macular Edema Due to Branch Retinal Vein Occlusion: 1-Year Prospective Study.

Authors:  Yusuke Arai; Hidenori Takahashi; Satoru Inoda; Shinichi Sakamoto; Xue Tan; Yuji Inoue; Satoko Tominaga; Hidetoshi Kawashima; Yasuo Yanagi
Journal:  J Clin Med       Date:  2020-07-23       Impact factor: 4.241

6.  The role of IL-6-174 G/C polymorphism and intraocular IL-6 levels in the pathogenesis of ocular diseases: a systematic review and meta-analysis.

Authors:  Zulvikar Syambani Ulhaq; Gita Vita Soraya; Lely Retno Wulandari
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

Review 7.  A Review of Intraocular Biomolecules in Retinal Vein Occlusion: Toward Potential Biomarkers for Companion Diagnostics.

Authors:  Bingjie Wang; Xiao Zhang; Huan Chen; Adrian Koh; Chan Zhao; Youxin Chen
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.